Navigation Links
Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials

nnel recently deployed in the Middle East, 76% reported at least one episode of diarrhoea and more than 50% reported multiple episodes.

Current travel patterns suggest that in 2020 there will be about 190 million susceptible individuals travelling from significant economies to regions at risk of TD. Under current conditions, 20% - 90% of these individuals would be expected to develop TD within two weeks of arrival. Similar numbers of individuals are likely to visit regions at intermediate risk of TD and about 8 _ 20% of these individuals would be expected to develop TD.

Antibiotics are frequently prescribed to treat infection and anti-diarrhoeal agents are used to treat the symptoms, but at present there is no commercially available vaccine to address Campylobacter jejuni.

ACE BioSciences

ACE BioSciences is an emerging pharmaceutical company focused on developing novel protein-based vaccines and antibodies to address infectious diseases. It has unique expertise in the extraction and analysis of the cell surface proteins used by pathogens (eg bacteria, viruses and fungi) to interact with and infect human host cells. ACE BioSciences aims to develop a portfolio of products independently and in collaboration with other companies. In addition to ACE393, the company is working on a vaccine for Streptococcus pneumoniae, the bacterium responsible for Pneumococcal disease. The market for a Streptococcus product would be multibillion and ACE BioSciences aims to partner the project in the coming year. The company recently began work on a programme to address ETEC (enterotoxigeneic E coli), which is the primary cause of TD around the world.

In December 2005, ACE BioSciences announced a collaborative agreement with the Aeras Global TB Vaccine Foundation whereby ACE BioSciences will support the characterization of second-generation BCG-based tuberculosis (TB) vaccines under development by Aeras. In November 2005, ACE BioSciences and the Dutch bi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
10. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
11. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
Post Your Comments:
(Date:7/30/2015)... 30, 2015 Mettler-Toledo International Inc. (NYSE: ... Provided below are the highlights: , Sales ... with the prior year. Reported sales decreased 4% as ... , Net earnings per diluted share as reported ... period. Adjusted EPS was $2.80 , an increase ...
(Date:7/30/2015)...  EP Global Communications, Inc. (Public OTC: EPGL) announced today ... Company about discussing EPGL,s electronic contact lens technologies.  ... 3, 2015.  Novartis CEO Joe Jimenez ... electronic contact lens market could be worth tens ... years.  Novartis partnered with Google in 2014 to ...
(Date:7/30/2015)... 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the second quarter ending June 30, 2015. ... across the organization.  We are excited to be near ... trial ever conducted with topline results expected in the ... Officer, PTC Therapeutics, Inc. "Translarna is now commercially available ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... Inc. (OTCPK: SNDY) is pleased to announce the launch ... on Friday July 1, 2011. The online venue ... customers and includes comprehensive information for shareholders, investors and ... to allow for easy-to-use functionality, allowing users to quickly ...
... ARBOR, Mich., June 23, 2011 Adeona Pharmaceuticals, Inc. ... innovative medicines for serious central nervous system diseases, announced ... zinc-based therapies to include a planned Phase IIb clinical ... also known as Lou Gehrig,s Disease. Preparations are underway ...
Cached Medicine Technology:Solos Endoscopy, Inc. To Launch New Corporate Website 2Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease (ALS) 2Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease (ALS) 3Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease (ALS) 4Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease (ALS) 5Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease (ALS) 6Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease (ALS) 7
(Date:7/31/2015)... ... 2015 , ... In the most recent testosterone lawsuit news related ... of Illinois, Androgel testosterone attorneys report that a “Mini Status Conference” was held recently, ... the minutes of the status conference, which was held that day, according to court ...
(Date:7/31/2015)... ... July 31, 2015 , ... India Network Foundation sponsors visitor ... study or family visit for the past 25 years. As India Network offers coverage ... to travel and spend time with their children and grand children. India Network ...
(Date:7/31/2015)... ... July 31, 2015 , ... David Gilpin, M.D., a board ... potential Nashville area sinus sufferers about the benefits of Balloon Sinuplasty. ... someone is a good candidate for Balloon Sinuplasty. The questionnaire asks questions about ...
(Date:7/30/2015)... ... 2015 , ... Dale Sky Jones, Executive Chancellor of Oaksterdam University , ... Professionals Expo held at the Caribe Royal All Suites Hotel and Convention Center in ... is the largest medical cannabis expo in the country and this year’s expo will ...
(Date:7/30/2015)... , ... July 31, 2015 , ... On July 22nd ... in Manatee county to discuss plausible solutions for controlling the heroin outbreak. Ultimately the ... of an overdose is largely perpetuating the heroin crisis in North Florida. The task ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3
... LLC and Flexadren, LLC, manufacturers and distributors of tablet ... in joint support and pain relief, announced today that ... did not prevail in its claims against CetylMax(R) and ... Federal litigation between CetylMax(R) and Flexadren(R) and Imagenetix. , ...
... Mission Viejo general surgeon Juan Carlos Cobo, MD ... Protection Trust (MPT) Board of Trustees. MPT is the medical ... (CAP). Dr. Cobo,s election occurred at the organization,s annual meeting ... family practitioner who presided as chair since 1986. Dr. ...
... With yet another tragedy in the headlines, Pennsylvania ... protect residents of our state,s assisted living facilities. , ... practices such as those that forced the Department of ... facility. , , Earlier this month, an aide ...
... by Carnegie Mellon University computer scientists has revealed ... the fruit fly, Drosophila melanogaster, evolve during the ... relationships between fruit fly genes change over time, ... details of those changes as they occur. The ...
... June 22 Providence Tarzana Medical Center on Friday ... generation in imaging - the Ziehm Vision RFD - in this ... of a patient who had suffered a small stroke. , ... staff at Tarzana, liked what he saw in the crystal-clear image ...
... Foundation of America (LFA) is seeking proposals for grant ... potentially fatal autoimmune disease. Grants will support areas of ... The purposes of the studies are to advance adult ... for lupus and address key understanding of pediatric/adolescent lupus ...
Cached Medicine News:Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 2Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 3Health News:Dr. Juan Carlos Cobo Newly-Elected Chair of the Mutual Protection Trust Board of Trustees 2Health News:Death at Assisted Living Facility Points to Desperate Need for Better Regulations from the State 2Health News:Death at Assisted Living Facility Points to Desperate Need for Better Regulations from the State 3Health News:Carnegie Mellon algorithm charts evolution of genetic networks during fruit fly life cycle 2Health News:Carnegie Mellon algorithm charts evolution of genetic networks during fruit fly life cycle 3Health News:Providence Tarzana Surgeon First in U.S. to Use New State-of-the-Art Imaging Tool 2Health News:Lupus Foundation of America Seeks Proposals for Research Studies on Childhood Lupus and Stem Cell Transplantation 2
... Quick & Easy Adjustment Of Blade Separation ... And Patient Comfort (Unlike Spring Action Speculum ... The Blades. No Laborious, Tedious, Slow Screw ... , ,Available In Either Solid Blade Or ...
... Special Low-profile Hourglass Jaw Design ... Through A Minimal Incision.,Mirror Polished Blades ... Acting Handle Mechanism Offers Control Over ... Prevent The Lens From Tilting During ...
... The 0.1mm Pierce Tip Opening ... Flap, Without The Need For A Separate Cystotome. ... Grasping Positions Without Elevating The Incision.,The Distal Jaws ... Blades Help To Prevent Inadvertent Pick Up Of ...
2.5V Halogen source, fiber-optic delivery, 3X magnification, pocket-sized....
Medicine Products: